Alex Battaglia1, Annette Lualhati, Harrison Lin, Raoul Burchette, Roberto Cueva. 1. *Department of Otolaryngology, Head and Neck Surgery, Southern California Permanente Medical Group, San Diego; and †Department of Research and Evaluation, Regional Offices of Southern California Permanente Medical Group, Pasadena, California, U.S.A.
Abstract
OBJECTIVE: To compare combination therapy (high-dose prednisone taper (HDPT) + intratympanic dexamethasone (IT-Dex)) hearing recovery results in ISSNHL patients with those treated with HDPT alone. DESIGN: Prospective, multicentered trial. SETTING: Tertiary referral center. PATIENTS: Eighty ISSNHL patients with class C or D hearing. INTERVENTION: Eighty qualifying patients were treated with IT-Dex (10 mg/ml) every week for 3 weeks concomitant with HDPT (60 mg/d for 7 d with 7-d taper) and followed prospectively. MAIN OUTCOME MEASURE(S): Four-tone pure tone average (PTA) at 0.25, 0.5, 1, and 2 kHz and speech discrimination scores (SDS) 2 months posttreatment; Hearing results compared retrospectively with those of 59 ISSNHL treated with HDPT alone. RESULTS: Combination therapy and HDPT alone both provided a statistically significant benefit in audiometric parameters, especially if treated within 7 days of onset. However, 49% versus 29% (p = 0.02) of class D patients receiving combination therapy versus HDPT achieved serviceable hearing. Patients receiving combination therapy versus HDPT experienced a significantly greater improvement in PTA (34.1 ± 27 dB versus 12.0 ± 21 dB; p < 0.0001) and SDS (49.9.2 ± 38% versus 19.2 ± 36%; p < 0.0001) while achieving a significantly better final PTA (50.6 ± 28 dB versus 65.5 ± 29 dB; p = 0.005) and SDS (62.4 ± 40% versus 44.7 ± 41%; p = 0.01). Approximately 56% of class D and 40% of profound patients treated within 7 days with combination therapy achieved serviceable hearing. CONCLUSION: Combination therapy offers ISSNHL patients the highest likelihood of achieving class A and B hearing. Differential results with combination therapy and HDPT compared with previous studies suggest time- and dose-dependent responses to the treatment of ISSNHL.
OBJECTIVE: To compare combination therapy (high-dose prednisone taper (HDPT) + intratympanic dexamethasone (IT-Dex)) hearing recovery results in ISSNHL patients with those treated with HDPT alone. DESIGN: Prospective, multicentered trial. SETTING: Tertiary referral center. PATIENTS: Eighty ISSNHL patients with class C or D hearing. INTERVENTION: Eighty qualifying patients were treated with IT-Dex (10 mg/ml) every week for 3 weeks concomitant with HDPT (60 mg/d for 7 d with 7-d taper) and followed prospectively. MAIN OUTCOME MEASURE(S): Four-tone pure tone average (PTA) at 0.25, 0.5, 1, and 2 kHz and speech discrimination scores (SDS) 2 months posttreatment; Hearing results compared retrospectively with those of 59 ISSNHL treated with HDPT alone. RESULTS: Combination therapy and HDPT alone both provided a statistically significant benefit in audiometric parameters, especially if treated within 7 days of onset. However, 49% versus 29% (p = 0.02) of class D patients receiving combination therapy versus HDPT achieved serviceable hearing. Patients receiving combination therapy versus HDPT experienced a significantly greater improvement in PTA (34.1 ± 27 dB versus 12.0 ± 21 dB; p < 0.0001) and SDS (49.9.2 ± 38% versus 19.2 ± 36%; p < 0.0001) while achieving a significantly better final PTA (50.6 ± 28 dB versus 65.5 ± 29 dB; p = 0.005) and SDS (62.4 ± 40% versus 44.7 ± 41%; p = 0.01). Approximately 56% of class D and 40% of profound patients treated within 7 days with combination therapy achieved serviceable hearing. CONCLUSION: Combination therapy offers ISSNHL patients the highest likelihood of achieving class A and B hearing. Differential results with combination therapy and HDPT compared with previous studies suggest time- and dose-dependent responses to the treatment of ISSNHL.
Authors: Stefan K Plontke; Christoph Meisner; Sumit Agrawal; Per Cayé-Thomasen; Kevin Galbraith; Anthony A Mikulec; Lorne Parnes; Yaamini Premakumar; Julia Reiber; Anne Gm Schilder; Arne Liebau Journal: Cochrane Database Syst Rev Date: 2022-07-22
Authors: L Sutton; V Schartinger; C Url; J Schmutzhard; D Lechner; C Kavasogullari; J S Sandhu; A Shaida; R Laszig; J Loehler; S Plontke; H Riechelmann; M Lechner Journal: Eur Arch Otorhinolaryngol Date: 2018-03-31 Impact factor: 2.503